Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial
NCT00939380 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 212
Last updated 2016-03-10
Summary
The investigators have developed a parent social-cognitive processing intervention (P-SCIP) to help decrease distress among parent caregivers of children undergoing hematopoietic stem cell transplant (HSCT). The investigators will evaluate the efficacy of P-SCIP in reducing short- and long-term distress and parenting stress among 300 parents of children undergoing HSCT. P-SCIP will be delivered during the child's inpatient HSCT hospitalization and is specifically designed to improve parent social (e.g., sharing concerns) and cognitive (e.g., acceptance) processing of the transplant experience. The intervention includes five in-person sessions that are accompanied by an interactive CD-ROM. The CD-ROM complements the materials in the in-person sessions and provides parents with the opportunity to enhance and deepen their cognitive and social processing of the HSCT experience. The intervention will be tested against best-practices psychosocial care (BPC) available in four enriched pediatric HSCT settings across the United States. P-SCIP will be provided to both Spanish- and English-speaking parents. Participants will complete measures of psychological distress, well-being, and social and cognitive processing at the time of HSCT, two, six and twelve months after HSCT. Research questions will address the effects of P-SCIP versus BPC on parent psychological adaptation and social and cognitive processing, as well as evaluate parent personal resources as well as child medical course variables that contribute to intervention response. The investigators will also examine barriers to participation in the intervention by comparing barriers to participation among parents who refuse participation in the trial and parents who accept.
Conditions
- Childhood Cancers
Interventions
- BEHAVIORAL
-
Behavioral intervention sessions
Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
- OTHER
-
CD-ROM
Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
- OTHER
-
DVD and pamphlet
Participants receive a "Discovery to Recovery" DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet "Top Tips for Parent Caregivers During the BMT Process" published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD.
- OTHER
-
Respite care
Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Children's Hospital Los Angeles
collaborator OTHER - collaborator OTHER
-
Emory University
collaborator OTHER -
Memorial Sloan Kettering Cancer Center
collaborator OTHER -
University of Medicine and Dentistry of New Jersey
collaborator OTHER -
Icahn School of Medicine at Mount Sinai
collaborator OTHER -
Weill Medical College of Cornell University
collaborator OTHER -
National Marrow Donor Program
collaborator OTHER -
Rutgers, The State University of New Jersey
lead OTHER
Principal Investigators
-
Sharon L Manne, Ph.D. · Rutgers Cancer Institute of New Jersey
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2015-01-31
- Completion
- 2015-05-31
Countries
- United States
Study Locations
More Related Trials
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
NCT00782145 ·Status: COMPLETED ·Phase: PHASE3
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
NCT03970096 ·Status: RECRUITING ·Phase: PHASE2
-
Conditioning SCID Infants Diagnosed Early
NCT03619551 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Siplizumab for Sickle Cell Disease Transplant
NCT06078696 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
NCT00795132 ·Status: COMPLETED ·Phase: PHASE2
-
A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease
NCT01279616 ·Status: TERMINATED ·Phase: PHASE2
-
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
NCT00619879 ·Status: COMPLETED
-
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
NCT05515029 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
NCT00382109 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
NCT03019809 ·Status: UNKNOWN ·Phase: PHASE2
-
Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
NCT02120157 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation
NCT06865352 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
NCT06756152 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases
NCT00613561 ·Status: UNKNOWN ·Phase: PHASE2
-
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
NCT00317785 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
NCT00047268 ·Status: UNKNOWN ·Phase: PHASE3
-
Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome
NCT03198195 ·Status: UNKNOWN
-
Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
NCT04018937 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
NCT04937634 ·Status: UNKNOWN ·Phase: PHASE1
-
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
NCT04776850 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells
NCT02512679 ·Status: TERMINATED ·Phase: PHASE2
-
Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00152139 ·Status: COMPLETED ·Phase: PHASE3
-
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus
NCT04370795 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Pharmacokinetic Study of Melphalan in Children
NCT02390544 ·Status: COMPLETED ·Phase: PHASE1